Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolinza in Recurrent/Metastatic Urothelial Carcinoma
NCT00363883Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2006
- Primary completion
- Dec 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Jun 2006; status: terminated.
02
Drugs
vorinostat
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00363883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363883.